HBV peptide–major histocompatibility complex

The HBV peptide–MHC complex is a molecular assembly consisting of an HBV-derived peptide bound in the peptide-binding groove of an MHC molecule (usually class I for CD8+ cytotoxic T cell activation or class II for CD4+ helper T cell activation). Presentation of HBV peptides by MHC is essential for antiviral immune responses, as it enables T cells to recognize and eliminate HBV-infected cells. The efficiency and specificity of this process depend on the peptide sequence, the MHC allele (notably HLA-A2 and its polymorphic forms in humans), and the interaction interface between peptide, MHC, and T cell receptor. Structural studies reveal that minor variations in MHC alleles can substantially alter peptide conformation and TCR binding affinity, providing direct pathways for vaccine optimization and rational immunotherapy design. Therapeutic approaches, including engineered T cells and TCR-like antibodies, aim to exploit this complex to selectively clear infected cells, but challenges remain due to antigen-processing efficiency, HLA polymorphism, and potential safety concerns like off-target cytotoxicity.

Other names

HBV peptide–HLA complexHBV pMHCHBV antigen–MHC complex

Immunotherapy: engineered T cells or antibodies recognize HBV peptide–MHC complexes on infected hepatocytes, leading to cell elimination. Vaccine: designed peptides presented by MHC to activate effective T cell responses.